Healthy men to test cancer Drug's new recipe
NCT ID NCT07619001
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study checks whether AK104, an experimental cancer drug, behaves the same in the body when made at a new manufacturing site versus the original site. It involves 158 healthy Chinese men who will get a single low dose of the drug. The goal is to compare drug levels in the blood, not to treat any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AK104 (anti-PD-1/CTLA-4 bispecific antibody)
- What this could lead to
- If successful, this could confirm that the drug made at the new site is equivalent to the original, supporting broader manufacturing flexibility.
- What could go wrong
- This is an early-phase study in healthy volunteers, not patients. It only checks drug levels in the blood, not whether the drug works for any disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY MALE ADULTS PARTICIPANTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Zhejiang Xiaoshan Hospital
Hangzhou, Zhejiang, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.